NCT06193863 - An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Prevention of Venous ThromboembolismCongenital Heart DiseaseFontan ProcedureChildren

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

At the discretion of the treating physician, based on the recommendations written in the local product information.

Trial Locations (1)

RECRUITING

Many Locations, Multiple Locations